Here we describe the design and protocol of the COMPAS study, which is the first prospective cohort study of SCC in patients with stroke, evaluating both patients and controls, while at the same time a wide range of variables is taken into account.
To assess the relation between the previous risk factors and stroke severity at presentation, the relationship between NIHSS level and hypertension, dyslipidemia, diabetes mellitus, cardio-embolic strokes, and history of previous stroke was evaluated.
Using analysis of variance (ANOVA) the effects of tPA, ischemic stroke, anesthesia, and the interaction of tPA*ischemic stroke were evaluated.
The mechanism of stroke was evaluated according to Trial of Org10172 in Acute Stroke Treatment (TOAST) criteria [ 14].
Participants: Individuals (n = 459) who sustained an eligible stroke were evaluated prospectively using standardized assessments at enrollment (within 14 days of stroke onset, 8.8 ± 3.5 days).
Time to stroke was evaluated by Cox proportional hazards models.There was no association between time to stroke and lipoprotein-associated phospholipase A2, monocyte chemoattractant protein-1, resistin, matrix metalloproteinase-9, N-terminal fragment of pro-B-type natriuretic peptide, soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1, or soluble CD40 ligand.
The primary definition of major adverse cardiovascular events was the composite of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke or the composite of death from any cause, non-fatal myocardial infarction, and non-fatal stroke as evaluated by universal clinical guidelines.
18 20 Fatal+non-fatal stroke was evaluated for five different insulin-exposure contrasts of which two exposure contrasts indicated risk differences in fatal+non-fatal stroke: other insulin regimen versus long-acting/intermediate-acting insulin (HR=1.20, 95% CI 1.04 to 1.40) and insulin aspart versus regular human insulin (HR=0.58, 95% CI 0.45 to 0.74).
This study reports a good 6-month outcome for stroke patients evaluated by telemedicine or telephone.
From there, current and future initiatives in the development of clinical trials in pediatric stroke are evaluated.
